Sartorius Stedim Biotech will add a portfolio of recombinant albumin-based products used in drug manufacture and a 72,000 square-foot production facility through the acquisition of Albumedix. During its second quarter financial call last month, bioprocess vendor Sartorius spoke about its desire to acquire complementary technologies and innovation through a war chest of around €10 billion ($10.2 billion) firepower at its disposal. Less than three weeks on, and the firm has pulled the trigger, agreeing to buy Albumedix for approximately £415…